Support of Clinical Trial - The Effect of Regular Exercise & Intermittent Rapamycin Dosing
Stage: Phase 2a Clinical Trial
Area: Drug repurposing
VitaDAO recognizes the importance of credible science in the field of healthspan and longevity research. One aspect of current longevity research that remains challenging is the translation of research from model organisms to humans, and the clinical trials regime that is imposed on new interventions. There is a view that a number of currently approved drugs - those that have long since completed the regulatory hurdles - have shown observable, incremental effects on longevity. One such drug is Rapamycin.
Rapamycin is an approved drug for prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. The proposed human clinical trial is meant to establish whether intermittent Rapamycin use demonstrates a functional improvement in frailty and sarcopenia endpoints.
Aims, Hypothesis & Results
Rapamycin is a best-in class-treatment, meaning it provides one of our strongest chances of seeing healthspan improving effects - yet surprisingly, few human trials have tested its healthspan effects.
As a Phase 2a trial in humans - focused on functional improvements in sarcopenia - this study will support our understanding of Rapamycin impacts on ageing related decline in physical function, but also work towards establishing a framework for regulatory approval of interventions that are preventative in nature related to ageing.
The clinical trial protocol can be found here: https://drive.google.com/file/d/1AP1L9JjGdnZgFmZ4sEDCWnp_2-g70-SP/view
In contrast to the ongoing PEARL trial for rapamycin and ageing (NCT04488601), this proposed trial will measure muscle power and strength by combining rapamycin intake with an exercise regimen. The primary outcome for this proposed trial is the 30-second chair test, which is a robust and clinically relevant marker of performance. In addition, several secondary outcomes will be measured including but not limited to: community balance and mobility, hand grip strength, 6-minute walk test, DNA methylation age, and serum levels of NAD+, cholesterol, and S6K. Importantly, this Phase 2 study is not powered enough to say that Rapamycin + exercise is better than exercise alone, instead it will be used to determine safety and some preliminary results. This proposed trial will be a stepping stone to a much larger study involving ~400-500 individuals.
Phase 2a Clinical Trial: Regular Exercise & Intermittent Rapamycin Dosing
Required Funding: $400,000 (VitaDAO providing $50,000)
Duration: 13 weeks study schedule plus recruitment and data analysis
VitaDAO Board Evaluation Writeup
Dr. Brad Stanfield is a medical doctor who has developed a strong following on YouTube for his informative and well researched videos on healthspan related interventions and science, and is an asset to the longevity community.
There is a large amount of literature from numerous organisms showing that rapamycin treatment can lead to improvements in healthspan/lifespan. This trial, aiming to test the effect of rapamycin on age-related frailty and sarcopenia, has a robust study protocol with the potential to lead to a more rigorous phase 3 trial.
The budget for the clinical trial is $400,000. VitaDAO will provide $50,000 USD (1/8th of the project budget) and look to activate our community to solicit more funding. In the United States, Lifespan.io is supporting the fundraising for the trial as a 501(c)3 charity.
Though there is no immediate intellectual property for VitaDAO from this project, our support is intended to advocate for further research into off-label use of approved, off-patent drugs and show our support for innovative and crowdsourced funding of research. This is complementary to VitaDAO’s support of CrowdFundedCures.org, and the social impact bond model in VDP-17.
Non Consectetur Necessitatibus
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Eum Harum Asperiores Id
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Ex Temporibus Perferendis
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Earum Est Dolorem
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Aperiam Et Quis Et
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Voluptas Quam Sapiente
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut Accusantium Ut
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Discover more projects & initiatives
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.
BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.
ExcepGen Inc - RNA therapeutics for longevity
ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.